Elaine Chen from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials - 6 days ago AstraZeneca falls on reports of Chinese probe - 11 days ago STAT+: Novo Nordisk reports continued growth in obesity drug sales - 12 days ago Investors reevaluate this year’s obesity darling - 12 days ago STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - 16 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 24 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago STAT+: Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago More evidence on GLP-1s and opioid addiction - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago Can GLP-1 drugs help with type 1 diabetes? - 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Moderna cuts spending, and Sarepta’s ‘curse’ on Califf - 2 months ago STAT+: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago BioMarin’s big day today - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago Does Ozempic increase the risk of suicidal thoughts? - 3 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 3 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Moderna is still in a Covid hangover - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago venBio raises $528 million for its fifth fund - 4 months ago Merck lays off workers amid rough pharma job market - 4 months ago Contradictory coverage decisions in North Carolina - 4 months ago STAT+: Gilead’s chief medical officer to leave as R&D efforts stall - 4 months ago It’s happy hour (for now) for Alnylam - 4 months ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago Can you get satiety with GLP-1s without the nausea? - 4 months ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 4 months ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 4 months ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 5 months ago What do Parkinson’s and obesity have in common? - 5 months ago STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease - 6 months ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 6 months ago STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor - 7 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 7 months ago Large trial challenges common practice of prescribing beta blockers after heart attack - 7 months ago STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills - 7 months ago STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure - 8 months ago Parkinson’s disease may be helped by GLP-1 drug, new study finds - 8 months ago Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds - 8 months ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 8 months ago STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles - 8 months ago STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label - 8 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Novo Nordisk reports continued growth in obesity drug sales - 12 days ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 3 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 17 days ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - about 2 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 2 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 2 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 3 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 3 months ago Listen: Drug pricing drops & psychedelics under fire - 3 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 4 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 4 months ago
5	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 24 days ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 5 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 24 days ago
7	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 4 months ago
8	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 5 months ago
9	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 5 months ago